![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
307kB |
| Item Type: | Editorial |
|---|---|
| Title: | VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab |
| Creators Name: | Pawlitzki, M. and Teuber, J. and Campe, C. and Wagner, M. and Schuart, C. and Paul, F. and Bittner, D. |
| Abstract: | Natalizumab (NTZ) was the first approved humanized monoclonal antibody in highly active relapsing remitting MS (RRMS). Because of the mechanism of inhibiting the migration of immune cells through the blood-brain barrier into the CNS, NTZ is associated with an increased risk of progressive multifocal leukoencephalopathy (PML) by the John Cunningham virus (JCV). Infections with other neurotropic viruses are rarely reported. We present a case of rapid retinal necrosis induced by varicella zoster virus (VZV) in a patient with RRMS under long-term NTZ treatment. |
| Source: | Neurology Neuroimmunology & Neuroinflammation |
| ISSN: | 2332-7812 |
| Publisher: | American Academy of Neurology |
| Volume: | 5 |
| Number: | 5 |
| Page Range: | e475 |
| Date: | 1 September 2018 |
| Official Publication: | https://doi.org/10.1212/NXI.0000000000000475 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
